New Oral Antibiotic Shows 90% Cure Rate for Gonorrhoea

A single pill could soon make treating one of the world's most common sexually transmitted infections dramatically easier.

An international clinical trial involving nearly 930 people across five countries has shown that zoliflodacin, a new oral antibiotic, cures gonorrhoea in more than 90% of cases. The results, published in The Lancet, come at a critical time as the bacteria causing gonorrhoea develops resistance to standard treatments.

Gonorrhoea affects millions worldwide each year. The infection can cause pain and discharge, but often goes unnoticed, allowing it to spread silently and potentially lead to serious complications like infertility and pelvic inflammatory disease.

The real concern keeping health officials up at night is antimicrobial resistance. Between 2022 and 2024, resistance to the two most commonly used antibiotics jumped from 2 in every 100 cases to 11 in every 100 cases. The World Health Organization has warned that without new treatments, gonorrhoea could become nearly impossible to cure with existing drugs.

Zoliflodacin attacks the bacteria differently than current antibiotics. It blocks an enzyme the bacteria need to copy their DNA, stopping them from multiplying without triggering the resistance mechanisms they've developed against other drugs.

The phase III trial tested the antibiotic in the United States, South Africa, Thailand, Belgium and the Netherlands across 17 clinics. Participants received either zoliflodacin or the current standard treatment, which requires both an injection and oral medication.

The Bright Side

Beyond its effectiveness, zoliflodacin's biggest advantage might be its simplicity. Current treatment requires an intramuscular injection, which means a clinic visit and trained medical staff. A single oral dose could reach more people faster, reducing transmission chains before they start.

Early treatment matters enormously for sexually transmitted infections. The faster someone gets treated, the less time they have to unknowingly spread the infection to partners. An oral option also removes barriers like needle anxiety or limited access to injection facilities.

The drug still needs regulatory approval before doctors can prescribe it. Until then, current injectable treatments remain the recommended therapy and continue to work effectively for most cases.

The World Health Organization has set an ambitious goal to substantially reduce gonorrhoea infections by 2030. New treatments like zoliflodacin represent one piece of that puzzle, alongside prevention education, early testing, and careful antibiotic stewardship to preserve the drugs we have.

The development shows how targeted research can meet urgent public health needs. As bacteria evolve, so does our ability to outsmart them with innovative solutions that work through entirely new pathways.

For the millions affected by gonorrhoea each year, this breakthrough brings real hope for simpler, more accessible treatment when and where it's needed most.